Circulating Non-coding RNAs as Diagnostic and Prognostic Markers of Human Diseases
Circulating non-coding RNAs play a crucial role as diagnostic and prognostic markers in various human diseases. Edited by Kyriacos N. Felekkis and Christos Papaneophytou, this special issue compiles research from the International Journal of Molecular Sciences, highlighting the significance of microRNAs and circular RNAs in cancer diagnosis and other health conditions. Each article examines specific non-coding RNAs, their expression patterns, and their potential as biomarkers for early detection and treatment response. This compilation is essential for researchers and healthcare professionals interested in molecular diagnostics and therapeutic strategies.
Key Points
Explores the role of circulating non-coding RNAs in cancer diagnosis and prognosis
Includes studies on microRNA expression in breast and lung cancer patients
Analyzes the impact of non-coding RNAs on chronic diseases like asthma and liver disease
Presents findings on the use of serum microRNAs as biomarkers for early disease detection
This link leads to an external site. We do not know or endorse its content, and are not responsible for its safety. Click the link to proceed only if you trust this site.
FAQs of Circulating Non-coding RNAs as Diagnostic and Prognostic Markers of Human Diseases
What are circulating non-coding RNAs and their significance in diseases?
Circulating non-coding RNAs, including microRNAs and circular RNAs, are crucial for understanding disease mechanisms and developing diagnostic tools. They are found in body fluids and can reflect pathological conditions, making them valuable biomarkers for various diseases. Their expression levels can indicate disease presence, progression, and response to treatment, particularly in cancers and chronic conditions. Research in this area aims to enhance early diagnosis and personalized medicine approaches.
How do circulating microRNAs function as biomarkers in cancer?
Circulating microRNAs can serve as biomarkers by reflecting the tumor microenvironment and the physiological state of the patient. For instance, specific microRNAs have been shown to correlate with tumor tissue expression levels, providing insights into the presence of cancer. Studies have demonstrated that certain microRNAs can be detected in the blood of patients with early-stage cancers, allowing for non-invasive diagnostic methods. This approach can lead to timely interventions and improved patient outcomes.
What research findings are presented regarding microRNA-206 and lung cancer?
Research highlighted in this special issue indicates that microRNA-206 and microRNA-1246 are promising markers for the early diagnosis of lung cancer, especially in patients with chronic obstructive pulmonary disease. These microRNAs exhibit altered expression patterns that correlate with disease progression, suggesting their potential utility in clinical settings. The findings emphasize the need for further investigation into their roles as diagnostic tools and their mechanisms in tumor biology.
What is the relationship between non-coding RNAs and chronic diseases?
Non-coding RNAs, such as microRNAs, have been implicated in the pathophysiology of chronic diseases like asthma and non-alcoholic fatty liver disease. For example, specific microRNAs have been associated with the modulation of inflammatory responses and metabolic pathways in these conditions. Understanding their roles can lead to the identification of novel therapeutic targets and biomarkers for disease management. This research underscores the importance of non-coding RNAs in chronic disease diagnostics and treatment strategies.
Related of Circulating Non-coding RNAs as Diagnostic and Prognostic Markers of Human Diseases
